Full title

Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study

Short Title

SARS-CoV-2 risk factors for mechanical ventilation

Authors and affiliations

Jean Regina¹, Matthaios Papadimitriou-Olivgeris^{1,2}, Raphaël Burger^{1,3}, Paraskevas Filippidis¹, Jonathan Tschopp¹, Florian Desgranges¹, Benjamin Viala¹, Eleftheria Kampouri¹, Laurence Rochat¹, David Haefliger¹, Mhedi Belkoniene^{1,3}, Carlos Fidalgo^{1,3}, Antonios Kritikos¹, Katia Jaton⁴, Laurence Senn², Pierre-Alexandre Bart³, Jean-Luc Pagani⁵, Oriol Manuel¹, Loïc Lhopitallier¹

¹Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

²Service of Hospital Preventive Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

³Service of Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

⁴Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

⁵Service of Intensive Care, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Keywords

COVID-19; SARS-CoV-2; Switzerland; Mechanical Ventilation

Contact

Corresponding author:

Loïc Lhopitallier, MD

Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne

Rue du Bugnon 46

Lausanne 1011, Switzerland

loic.lhopitallier@chuv.ch

+41795560320

Abstract

Background

Coronavirus disease 2019 (COVID-19) is now a global pandemic with Europe and the USA at

its epicenter. Little is known about risk factors for progression to severe disease in Europe.

This study aims to describe the epidemiology of COVID-19 patients in a Swiss university

hospital.

Methods

This retrospective observational study included all adult patients hospitalized with a

laboratory confirmed SARS-CoV-2 infection from March 1 to March 25, 2020. We extracted

data from electronic health records. The primary outcome was the need to mechanical

ventilation at day 14. We used multivariate logistic regression to identify risk factors for

mechanical ventilation. Follow-up was of at least 14 days.

Results

200 patients were included, of whom 37 (18.5%) needed mechanical ventilation at 14 days.

The median time from symptoms onset to mechanical ventilation was 9.5 days (IQR 7.00,

12.75). Multivariable regression showed increased odds of mechanical ventilation in males

(3.26, 1.21-9.8; p=0.025), in patients who presented with a qSOFA score ≥2 (6.02, 2.09-1.00)

18.82; p=0.001), with bilateral infiltrate (5.75, 1.91-21.06; p=0.004) or with a CRP of 40 mg/l

or greater (4.73, 1.51-18.58; p=0.013).

Conclusions

This study gives some insight in the epidemiology and clinical course of patients admitted in a European tertiary hospital with SARS-CoV-2 infection. Male sex, high qSOFA score, CRP of 40 mg/l or greater and a bilateral radiological infiltrate could help clinicians identify patients at high risk for mechanical ventilation.

Abbreviations

CCI	Charlson Comorbidity Index		
AKI	Acute Kidney Injury		
ARDS	Acute Respiratory Distress Syndrome		
LUH	Lausanne University Hospital		
EHR	Electronic Health Records		
CRP	C-Reactive Protein		
PCT	Procalcitonin		
MV	Mechanical ventilation		
SOFA score	Sequential Organ Failure Assessment score		
qSOFA score	quick SOFA score		
NEWS	National Early Warning score		
CRB-65 score	Confusion/Respiratory rate/Blood pressure/age2≥265 years score		
WHO	World Health Organization		

Introduction

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

respiratory failure requiring mechanical ventilation.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan (China) in December 2019. WHO, in February 2020, named the resulting disease COronaVirus Induced Disease 2019 (COVID-19) [1]. There is a wide spectrum of severity ranging from asymptomatic presentation to severe pneumonia requiring ventilator support and death [2]. Since March 2020, the pace of SARS-CoV-2 spread around the globe increased as the epidemic evolved to a pandemic [3]. Europe and the USA are now at the epicenter of the pandemic and face increasing number of severe cases. By April 14 2020, Switzerland registered 25580 cases, 2936 hospitalisation and 885 deaths [4]. Several studies described epidemiological characteristics of COVID-19 patients in China [2,5,6]. To our knowledge, to the exception of a study including critically ill patients [7], none has so far described epidemiology, risk factors and clinical course of COVID-19 patients in a European setting. We think that it is important to collect and analyse European data. The European population is older, with a likely different genetic background that may influence the evolution of disease and with different resources for responding to the outbreak. Furthermore, although many studies have modelled the risk of severe disease in Chinese patients, little is known about risk factors for progression to severe disease in Europe [8]. In the present study, we report the epidemiological and clinical characteristics of patients hospitalized for COVID-19 in a Swiss university hospital as well as risk factors for progressive

Methods 22 23 Study Setting 24 This study took place in Lausanne University Hospital (LUH), a one-thousand-bed tertiary 25 university hospital in Lausanne, Switzerland. LUH serves as a primary-level community 26 hospital for Lausanne (population circa 300'000 inhabitants) and as a referral hospital for 27 Western Switzerland (population circa 1 - 1.5 million inhabitants). LUH increased its 28 outbreak response capacity by setting up new intensive care units for the management of 29 COVID-19 patients. 30 31 Study Design and Participants 32 This retrospective observational study analysed all adult patients consecutively hospitalized 33 with a confirmed SARS-CoV-2 infection from March 1, 2020, to March 25, 2020. Patient's 34 initial physicians used local guidelines to decide on admission (only patients with risk factors 35 for severe disease or patients needing medical care were hospitalized). For all patients, we ensured of follow-up of up to at least 14 days, or up to discharge or death if they occurred 36 37 first. 38 Data collection 39 40 LUH electronic health record (EHR) provided epidemiological, clinical, radiological and 41 laboratory data. 42 Epidemiological data included age, sex, height, weight, and relevant comorbidities (including 43 a Charlson Comorbidities Index (CCI)). We collected data on clinical presentation, SARS-CoV-

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

2 treatments, concomitant treatments, non-pharmacological interventions and clinical course within LUH. We recorded radiological findings from reports of chest radiography or computed tomography (CT). We defined healthcare workers as professionals having direct contact with patients (nurses, physiotherapists, physicians, etc.) or patient samples. Laboratory data included full blood count, D-dimers, creatinine, highly sensitive cardiac Ttroponin, C-reactive protein (CRP), procalcitonin (PCT), ferritin, liver function tests, blood type and real-time PCR to detect SARS-CoV-2 [9]. We entered all data in an electronic clinical report form (eCRF) using the REDCap® platform (Research Electronic Data Capture v8.5.24, Vanderbilt University, Tennessee, USA) [10]. Fellows of the Infectious Diseases, Hospital Preventive Medicine and Internal Medicine Services at LUH entered the data and two of the authors (JR, MP) verified their integrity. Clinical management Treating physicians made all decisions regarding supportive care. Specialists in infectious diseases reviewed all SARS-CoV-2 treatment decisions according to the local recommendations. These included protease inhibitors (ritonavir-boosted lopinavir or atazanavir), hydroxychloroquine or remdesivir. Selected critically ill patients with high inflammatory markers (CRP, D-dimers, PCT and ferritin) received tocilizumab. The choice of treatment depended on drug availability, safety profile drug-drug interactions. Treating physicians discussed advance planning of care and do not resuscitate orders with all patients. Limitations of care were decided upon admission according to the patient's values and goals and the treating physician's appreciation. We categorized these limitations into

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

two levels: 1) no limitation; 2) limitation to the best supportive care provided in nonmonitored wards or intermediate care units but without mechanical ventilation (MV). Definition We defined a confirmed SARS-CoV-2 infection as a positive test for SARS-CoV-2 using realtime polymerase chain reaction (RT-PCR) technology in any respiratory sample. We classified infection as nosocomial if the onset of symptoms started more than 96 hours after admission for another indication. We defined obesity either as a body mass index (BMI) of 30 kg/m² or higher, or, when missing anthropometric data, a medical diagnosis of obesity. We used the Berlin definition for Acute Respiratory Distress Syndrome (ARDS) [11]. We defined shock as refractory hypotension requiring infusion of vasopressors. Acute kidney injury (AKI) was identified and classified according to the 2012 Kidney Disease Improving Global Outcome guidelines [12]. We defined liver injury as a 3-fold or greater increase in transaminase levels. (qSOFA) We calculated guick Seguential Organ Failure Assessment Confusion/Respiratory rate/Blood pressure/age®≥®65 years (CRB-65) score and National Early Warning Score (NEWS) were assessed according to their original descriptions [13-15]. We defined MV as invasive respiratory support through a laryngeal or a tracheostomy tube Outcome The primary outcome was the use of MV for respiratory failure attributed to SARS-CoV-2 pneumonia, within 14 days after admission.

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Statistics The number of cases diagnosed during the study period defined the sample size. Statistical analyses were performed using R software v3.6.2 (R Foundation for Statistical Computing; www.r-project.org). Categorical variables were presented as numbers (percentages), normally distributed continuous variables were presented as mean ± standard deviation (SD) and continuous variables with a skewed distribution were presented as median [interquartile range (IQR)]. For the descriptive analysis, we analysed proportions of categorical variables using chisquare goodness of fit test; we used Student t-test for normally distributed variables or Mann-Whitney-Wilcoxon test for continuous variables with a skewed distribution. We used a general linear model based on univariate and multivariate logistic regression to calculate odds ratio for MV. We excluded from the analysis, patients whose care was limited to the best supportive care and patients already mechanically ventilated on admission. To avoid bias resulting from treatment indication, we did not include SARS-CoV-2 specific treatments as variables in the model. To select predictive variables included in the multivariable analysis model, we first identified clinically relevant variables from the univariate analysis for which the p-value was less than 0.2. To avoid overfitting, the final multivariate model used only four variables chosen by a backward stepwise approach. For the inflammatory biomarkers, we converted continuous variables to categorical variables using cut-off values previously identified in the literature [6,16,17]. We did not impute any values for missing data.

Ethics

 This project was conducted in accordance with the Declaration of Helsinki, the principles of Good Clinical Practice and the Swiss Human Research Act (HRA). The project received approval from the Ethics Committee of canton Vaud, Switzerland (2020-00657) that waived the need for informed consent. All data were anonymized before analysis.

Results

Epidemiological characteristics

Overall, 200 patients with confirmed SARS-CoV-2 infection were hospitalized at LUH during the study period. In 54 (27.0%), care was agreed to be limited to best supportive care on admission, these patients were older and with more comorbidities (Table 1).

Median patient age was 70.0 years [IQR 55.0-81.0], ranging from 20.0 to 96.0 years. Eighty-three (43.0 %) of all inpatients were aged 65.0 years or younger. Median BMI was 26.02 [IQR 22.5-30.71]. Overall, 33 (16.5%) patients acquired nosocomial SARS-CoV-2 infection.

Table 1. Comparison of patients with and without limitation of care

	No limitation of	Limitation of care	<i>P</i> Value
	care		
n	146	54	
Age, years (median [IQR])	62.50 [52.00,	83.50 [80.00,	<0.001
	74.00]	88.00]	
Age group, years (n, %)			<0.001
18-30	7 (4.8)	1 (1.9)	
31-50	28 (19.2)	0 (0.0)	
51-65	47 (32.2)	3 (5.6)	
65-80	48 (32.9)	11 (20.4)	

>80			16 (11.0)	39 (72.2)	
Charlson (median [IQ	Comorbidity R])	Index	3.00 [1.00, 5.00]	7.00 [5.00, 9.00]	<0.001
Dementia (n	, %)		5 (3.4)	21 (38.9)	<0.001
Cancer (n, %	6)		16 (11.0)	10 (18.5)	0.24

One hundred and sixty (80.8 %) patients had at least one comorbidity, with a median Charlson Comorbidity Index of 4.0 [IQR 2.0-6.0]. Table 2 summarizes the characteristics of this population whose most frequent comorbidities were hypertension (43.5%), obesity (27.0%), diabetes (21.5%), coronary artery disease (17.5%) and chronic kidney disease (14.0%).

Fifty-one (26.2 %) patients were treated with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARBs). Fourteen (7.0 %) were treated with immunosuppressive drugs of which six (3.0 %) patients were transplant recipients (5 solidorgan and 1 haematopoietic stem-cell transplantation). Twenty-six (13.0%) patients had an active malignancy at the time of admission.

Table 2. Demographics, clinical, laboratory and radiographic findings of patients on

admission

		No mechanical	Mechanical	
	Overall	ventilation	ventilation	P Values
n	200	163	37	
Male sex (n, %)	120 (60.0)	91 (55.8)	29 (78.4)	0.019
	70.00 [55.00,	71.00 [55.00,	66.00 [57.00,	
Age, years (median [IQR])	81.00]	82.00]	79.00]	0.337
Age group, years (n, %)				0.231
18-30	8 (4.0)	8 (4.9)	0 (0.0)	

31-50	28 (14.0)	21 (12.9)	7 (18.9)	
51-65	50 (25.0)	39 (23.9)	11 (29.7)	
65-80	59 (29.5)	46 (28.2)	13 (35.1)	
>80	55 (27.5)	49 (30.1)	6 (16.2)	
Overweight (BMI>25 kg/m²)				
(n, %)	102 (51.0)	75 (46.0)	27 (73.0)	0.005
Obesity (BMI>30 kg/m ²) (n, %)	54 (27.0)	38 (23.3)	16 (43.2)	0.024
Body mass index, kg/m ²	26.02 [22.50,	25.30 [21.85,	26.99 [24.43,	
(median [IQR])	30.71]	30.18]	30.79]	0.107
Active smoking (n, %)	9 (4.5)	9 (5.6)	0 (0.0)	0.301
Pregnancy (n, %)	6 (7.5)	5 (6.9)	1 (12.5)	1
Healthcare worker (n, %)	7 (3.5)	4 (2.5)	3 (8.1)	0.236
Comorbidity (n, %)	160 (80.8)	134 (83.2)	26 (70.3)	0.116
Hypertension (n, %)	87 (43.5)	72 (44.2)	15 (40.5)	0.827
Atrial fibrillation (n, %)	19 (9.5)	17 (10.4)	2 (5.4)	0.528
Coronary artery	(5.5)		_ (3)	
disease (n, %)	35 (17.5)	29 (17.8)	6 (16.2)	1
Stroke (n, %)	21 (10.5)	19 (11.7)	2 (5.4)	0.411
Chronic kidney disease	(_0,0)		_ (0)	01.12
(n, %)	28 (14.0)	26 (16.0)	2 (5.4)	0.16
Chronic obstructive			_ (/	
pulmonary disease (n,				
%)	16 (8.0)	12 (7.4)	4 (10.8)	0.717
Asthma (n, %)	8 (4.0)	7 (4.3)	1 (2.7)	1
Diabetes (n, %)	43 (21.5)	35 (21.5)	8 (21.6)	1
Cirrhosis (n, %)	6 (3.0)	6 (3.7)	0 (0.0)	0.515
Charlson Comorbidity Index	4.00 [2.00,	4.00 [2.00,	4.00 [1.00,	
(median [IQR])	6.00]	7.00]	5.00]	0.141
Transplantation (n, %)	6 (3.0)	6 (3.7)	0 (0.0)	0.515
Hematopoietic stem	, ,	, ,	, ,	
cell transplantation (n,				
%)	1 (0.5)	1 (0.6)	0 (0.0)	1
Solid organ				
transplantation (n, %)	5 (2.5)	5 (3.1)	0 (0.0)	0.62
Cancer (n, %)	26 (13.0)	23 (14.1)	3 (8.1)	0.478
HIV infection (n, %)	3 (1.5)	2 (1.2)	1 (2.7)	1
Immunosupressive drugs (n,				
%)	14 (7.0)	14 (8.6)	0 (0.0)	0.136
ACE inhibitors or ARB II (n, %)	51 (26.2)	40 (25.0)	11 (31.4)	0.568
NSAIDs (n, %)	3 (1.5)	3 (1.9)	0 (0.0)	0.936
Duration of symptoms before				
test, days (mean (SD))	6.10 (4.29)	5.80 (4.34)	7.38 (3.86)	0.043
Fever (n, %)	131 (65.5)	104 (63.8)	27 (73.0)	0.386
Fatigue (n, %)	99 (49.5)	81 (49.7)	18 (48.6)	1
Cough (n, %)	124 (62.0)	95 (58.3)	29 (78.4)	0.037
Anosmia/Dysgeusia (n, %)	7 (3.5)	6 (3.7)	1 (2.7)	1
. , , , ,	. ,	, ,	. , ,	

Dyspnea (n, %)	98 (49.0)	69 (42.3)	29 (78.4)	<0.001
Arthralgia/Myalgia (n, %)	40 (20.0)	30 (18.4)	10 (27.0)	0.339
Nausea/Vomitting (n, %)	37 (18.5)	33 (20.2)	4 (10.8)	0.271
Diarrhea (n, %)	42 (21.0)	37 (22.7)	5 (13.5)	0.31
Loss of consciousness (n, %)	20 (10.0)	16 (9.8)	4 (10.8)	1
Confusion (n, %)	17 (8.5)	13 (8.0)	4 (10.8)	0.817
(.,, ,,,	38.20 [37.60,	38.15 [37.40,	38.70 [37.98,	0.027
Temperature (median [IQR])	38.73]	38.62]	39.12]	0.004
F (13.17	118.00			
Systolic blood pressure	[105.00,	119.00 [109.00,	110.00 [97.00,	
(median [IQR])	128.00]	130.00]	125.00]	0.023
	93.00 [82.00,	92.00 [82.00,	94.50 [88.00,	
Heart rate (median [IQR])	104.00]	102.25]	115.25]	0.035
Respiratory rate (median	24.00 [20.00,	23.00 [19.50,	31.00 [28.00,	
[IQR])	30.00]	28.00]	35.00]	<0.001
Glasgow Coma Scale = 15				
points (n, %)	180 (90.0)	148 (90.8)	32 (86.5)	0.653
,	28.00 [21.00,	26.00 [21.00,	44.50 [28.50,	
FiO2, percent (median [IQR])	40.00]	30.00]	71.25]	<0.001
Nosocomial SARS-CoV-2	•	-	-	
infection (n, %)	26 (13.1)	26 (16.0)	0 (0.0)	0.019
Co-infection on admission (n,				
%)	17 (8.5)	9 (5.5)	8 (21.6)	0.004
Any imaging (n, %)	182 (93.3)	145 (90.6)	37 (100.0)	0.150
Chest X-ray (n, %)	180/182 (98.9)	143/145 (96.6)	37/37 (100.0)	0.108
Lung scan (n, %)	17/182 (9.3)	11/145 (7.6)	6/37 (16.2)	0.122
Radiological infiltrate				
(n, %)	126/182 (69.2)	91/145 (62.8)	35/37 (94.6)	<0.001
Bilateral infiltrate (n,				
%)	97/182 (53.3)	65/145 (44.8)	32/37 (86.5)	<0.001
CRB-65 score				0.026*
0-1 (n, %)	122/190 (64.2)	105/153 (68.6)	17/37 (45.9)	
2 (n, %)	45/190 (23.7)	33/153 (21.6)	12/37 (32.4)	
3-5 (n, %)	23/190 (12.1)	15/153 (9.8)	8/37 (21.6)	
qSOFA score				<0.001*
0 (n, %)	68/196 (34.7)	65/159 (40.9)	3/37 (8.1)	
1 (n, %)	94/196 (48.0)	74/159 (46.5)	20/37 (54.1)	
2 (n, %)	28/196 (14.3)	17/159 (10.7)	11/37 (29.7)	
3 (n, %)	6/196 (3.1)	3/159 (1.9)	3/37 (8.1)	
NEWS score	, ,	, ,	. , ,	<0.001*
0 (n, %)	10/191 (5.2)	10/159 (6.3)	0/32 (0.0)	
1-4 (n, %)	59/191 (30.9)	57/159 (35.8)	2/32 (6.2)	
5-6 (n, %)	44/191 (23.0)	40/159 (25.2)	4/32 (12.5)	
7 or more (n, %)	78/191 (40.8)	52/159 (32.7)	26/32 (81.2)	
White blood cell count, x10 ⁹	5.60 [4.40,	5.30 [4.30,	6.50 [5.10,	
per L (median [IQR])	7.23]	6.80]	10.50]	0.003
per E (median [iQit])	1.23]	0.00]	10.50]	0.000

Lymphocytes count, x10 ⁹ per L	0.80 [0.60,	0.80 [0.57,	0.86 [0.63,	
(median [IQR])	1.21]	1.21]	1.15]	0.75
	202.00	-	-	
Platelets count, x10 ⁹ per L	[158.00,	206.00 [161.50,	185.00 [141.00,	
(median [IQR])	257.00	263.50]	237.00]	0.061
	966.00	-	1173.00	
D-dimers, ng/mL (median	[559.00,	908.00 [513.50,	[729.75,	
[IQR])	2020.00]	1961.00]	2455.50]	0.062
Creatinine, µmol/L (median	89.00 [71.50,	88.50 [70.00,	97.00 [82.00,	
[IQR])	115.00]	112.75]	127.00]	0.102
AKIN classification (n, %)				0.001*
0	152 (76.0)	133 (81.6)	19 (51.4)	
1	41 (20.5)	133 (81.6)	14 (37.8)	
2	4 (2.0)	2 (1.2)	2 (5.4)	
3	3 (1.5)	1 (0.6)	2 (5.4)	
	48.00 [19.00,	41.00 [15.00,	132.00 [57.00,	
CRP, mg/L (median [IQR])	103.50]	85.00]	198.00]	< 0.001
	0.14 [0.08,	0.11 [0.08,	0.21 [0.15,	
PCT, μg/L (median [IQR])	0.27]	0.23]	0.52]	< 0.001
	696.00		1546.00	
Serum ferritin, µg/L (median	[305.00,	628.50 [277.00,	[791.00,	
[IQR])	1546.00]	1252.25]	2255.00]	0.001
High-sensitive cardiac				
troponin T, ng/L (median	15.00 [6.50,	15.00 [6.00,	14.50 [7.75,	
[IQR])	32.00]	32.00]	29.75]	0.836
	43.50 [33.00,	42.00 [32.00,	66.00 [37.00,	
AST, U/L (median [IQR])	65.75]	58.00]	89.00]	0.005
	30.00 [19.00,	28.00 [19.00,	40.00 [22.00,	
ALT, U/L (median [IQR])	54.00]	46.50]	75.00]	0.028
Total bilirubin, μmol/L	8.00 [6.00,	8.00 [5.00,	10.00 [6.00,	
(median [IQR])	12.00]	11.00]	14.00]	0.1
ABO group done (n, %)	119 (59.5)	86 (52.8)	33 (89.2)	<0.001
ABO group (n, %)				0.449*
Α	49/119 (41.2)	39/86 (45.3)	10/33 (30.3)	
В	16/119 (13.4)	10/86 (11.6)	6/33 (18.2)	
AB	5/119 (4.2)	3/86 (3.5)	2/33 (6.1)	
0	49/119 (41.2)	34/86 (39.5)	15/33 (45.5)	

Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inflammatory drugs; CRB-65 score, Confusion/Respiratory rate/Blood pressure/age®≥№65 years score; qSOFA score, quick Sequential Organ Failure Assessment score; NEWS, National

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

Early Warning Score; AKIN, Acute Kidney Injury Network; CRP, C-reactive protein; PCT, procalcitonin; AST, aspartate transaminase; ALT, alanine transaminase. *χ² test comparing all subcategories. Clinical characteristics on admission The mean duration of symptoms preceding admission (or first positive SARS-CoV-2 test for nosocomial cases) was six days (SD 4.29). The most frequent symptoms at the time of testing were fever in 131 patients (65.5%), cough in 124 (62.0%), fatigue in 99 (49.5%) and dyspnoea in 98 (49.0%). Table 2 describes vital signs, qSOFA score, NEWS and CRB-65 scores on admission. Laboratory values and radiology Table 2 describes the median value of commonly measured inflammatory parameters (white blood cell count, CRP, procalcitonin, D-dimers and ferritin). Overall, 182 patients (93.3%) had at least one radiological exam, 126/182 of them (69.2%) presented new lung infiltrates which were bilateral for 97/126 (77.0%) of them. **Treatments** 118 (59.0%) of all patients received SARS-CoV-2 treatment (table 3). The most frequently prescribed medication were protease inhibitors in 103 patients (51.5%), hydroxychloroquine in 83 patients (41.5%) and remdesivir in 17 patients (8.5%). Seventeen (8.5%) patients received tocilizumab in adjunction to another SARS-CoV-2 treatment. Seventy-seven patients (38.5%) received two or more concomitant SARS-CoV-2 treatments. Seventy (35.0%) patients received antibiotics. One hundred and thirty-seven (68.5%) patients

required supplementary oxygen during the follow-up period.

Table 3. Treatments received by patients during the follow-up period

	Overall	No mechanical ventilation	Mechanical ventilation
n	200	163	37
Any SARS-CoV-2			
treatment (n, %)	118 (59.0)	83 (50.9)	35 (94.6)
Protease inhibitor (n, %)	103 (51.5)	71 (43.6)	32 (86.5)
Hydroxychloroquine (n,			
%)	83 (41.5)	57 (35.0)	26 (70.3)
Remdesivir (n, %)	17 (8.5)	0 (0.0)	17 (45.9)
Tocilizumab (n, %)	17 (8.5)	3 (1.8)	14 (37.8)
Any antibiotic treatment			
(n, %)	70 (35.0)	38 (23.3)	32 (86.5)

Clinical course

Table 4 summarizes patient's clinical course. At the end of the follow-up, 39 (19.5%) patients were still hospitalized, 101 (50.5%) patients were discharged, 21 (10.5%) patients were transferred to a rehabilitation centre and 14 (7.0%) to another acute care hospital. Twenty-five (12.5%) patients died during hospitalization.

Overall, 38 (19.0%) patients required mechanical ventilation, 37 (97.4%) of them before the 14th day and after a median of 2 days since admission (IQR 0.00 - 3.00). Median time from symptom onset to mechanical ventilation was 9.5 days (IQR 7.00 - 12.75]. Regarding patients requiring MV, 26 (68.4%) had a least one session of prone positioning, 24 (63.2%) received a vasopressor, 11 (28.9%) were eventually weaned from ventilator support and 11 (28.9%) died. The median duration of MV was 6 days (IQR 5.00 - 11.00). Twenty-two of the 38 patients (57.9%) requiring MW were admitted to new dedicated COVID-19 ICUs.

Table 4. Clinical course

195

196

197

198

203

	Overall
n	200
Time from hospitalization to oxygen need, days* (median [IQR])	0.00 [0.00, 1.00]
Time from symptoms onset to mechanical ventilation, days (median	
[IQR])	9.50 [7.00, 12.75]
Time from hospitalization to mechanical ventilation, days* (median	
[IQR])	2.00 [0.00, 3.00]
Duration of mechanical ventilation of extubated patients, days	
(median [IQR])	6.00 [5.00, 11.00]
Outcome	
Still Hospitalized (n, %)	39 (19.5)
Discharge at home (n, %)	101 (50.5)
Time from hospitalization to home discharge, days* (median [IQR])	6.00 [4.00, 9.00]
Readaptation (n, %)	21 (10.5)
Time from hospitalization to readaptation discharge, days* (median	
[IQR])	12.00 [8.00, 16.75]
Transfer at other acute care hospital (n, %)	14 (7.0)
Time from hospitalization to other acute care hospital transfer, days*	
(median [IQR])	6.00 [5.00, 9.00]
Death (n, %)	25 (12.5)
Time from hospitalization to death, days* (median [IQR])	8.00 [4.00, 10.00]

Complications

Table 5 describes complications during follow-up. The most frequent complications were ARDS (n = 44, 22.0%), acute confusional state (n = 30, 15.0%), acute kidney injury (n = 30, 15.0%), hospital-acquired pneumonia (HAP) (n = 26, 13.0%) and arrhythmia (n = 21, 10.5%) of patients.

204 Table 5. Complications during the follow-up period

	Overall	No mechanical ventilation	Mechanical ventilation	P Values
n	200	164	36	
Asthma or COPD				
exacerbation (n, %)	4 (2.0)	4 (2.4)	0 (0.0)	0.772
Community acquired	11 (5.5)	5 (3.0)	6 (16.7)	0.004

pneumonia (n, %)				
Hospital acquired				
pneumonia (n, %)	26 (13.0)	10 (6.1)	16 (44.4)	<0.001
Acute respiratory distress				
syndrome (n, %)	44 (22.0)	10 (6.1)	34 (94.4)	<0.001
Pneumothorax (n, %)	3 (1.5)	1 (0.6)	2 (5.6)	0.146
Pulmonary embolism (n, %)	6 (3.0)	4 (2.4)	2 (5.6)	0.65
Other thromboembolic				
event (n, %)	6 (3.0)	3 (1.8)	3 (8.3)	0.126
Acute confusional state (n,				
%)	30 (15.0)	23 (14.0)	7 (19.4)	0.571
Seizure (n, %)	1 (0.5)	0 (0.0)	1 (2.8)	0.404
Stroke (n, %)	6 (3.0)	4 (2.4)	2 (5.6)	0.65
Arrhythmia (n, %)	21 (10.5)	13 (7.9)	8 (22.2)	0.026
Myocarditis (n, %)	2 (1.0)	1 (0.6)	1 (2.8)	0.796
Heart failure (n, %)	10 (5.0)	9 (5.5)	1 (2.8)	0.8
Acute kidney injury (n, %)	30 (15.0)	13 (7.9)	17 (47.2)	<0.001
Septic shock (n, %)	12 (6.0)	1 (0.6)	11 (30.6)	<0.001
Acute hepatic injury (n, %)	11 (5.5)	6 (3.7)	5 (13.9)	0.042
Acute coronary syndrome				
(n, %)	3 (1.5)	1 (0.6)	2 (5.6)	0.146

Abbreviations: COPD: Chronic Obstructive Pulmonary Disease

Risk factors for mechanical ventilation

Of 200 patients included in the study, we included 145 (72.5%) in the analyses assessing the risk factors for mechanical ventilation (MV) (figure 1).

Figure 1. Patient's selection for univariate and multivariate models.

S1 Table summarizes unadjusted odds of MV at 14 days. Unadjusted odds of MV at 14 days were greater in males (odds ratio 2.65, 95% confidence interval 1.15 to 6.72) and in overweight patients (odds ratio 2.46, 95% confidence interval 1.11 to 5.81). None of the comorbidities increased the unadjusted risk MV at 14 days. Unadjusted odds of MV at 14

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

days were greater for patients presenting with dyspnoea (odds ratio 4.29, 95% confidence interval 1.86 to 10.85) on admission. NEWS score ≥7 (odds ratio 9.18, 95% confidence interval 3.66 to 26.55), qSOFA score ≥2 (odds ratio 6.86, 95% confidence interval 2.68 to 18.47) or a CRB-65 score ≥2 (odds ratio 4.64, 95% confidence interval 2.07 to 10.65) increased the unadjusted odds of MV. The presence of a radiological infiltrates increased the odds of mechanical ventilation (odds ratio 11.0, 95% confidence interval 3.14 to 70.45) as did the presence of a bilateral infiltrates (odds ratio 7.05, 95% confidence interval 2.75 to 21.87). Acute kidney injury on admission (odds ratio 4.27, 95% confidence interval 1.87 to 9.91), D-dimers of 1000 ng/ml or greater (odds ratio 3.28, 95% confidence interval 1.37 to 8.25), CRP of 40 mg/l or greater (odds ratio 6.79, 95% confidence interval 1.51 to 18.58) and PCT of 0.5 µg/l or greater (odds ratio 5.99, 95% confidence interval 1.52 to 29.66) increased the unadjusted odds of mechanical ventilation. Adjusted odds of mechanical ventilation at 14 days were greater in males (odds ratio 3.26, 95% confidence interval 1.21 to 9.8), in patients who presented with a qSOFA score ≥ 2 (odds ratio 6.02, 95% confidence interval 2.09 to 18.82), with bilateral infiltrate (odds ratio 5.75, 95% confidence interval 1.91 to 21.06) or with a CRP of 40 mg/l or greater (odds ratio 4.73, 95% confidence interval 1.51 to 18.58) on admission (Table 6).

Table 6. Adjusted risk factors associated with mechanical ventilation at 14 days

	Overall	No mechanical ventilation	Mechanical ventilation	Multivariate OR [95% CI]	<i>P</i> value
n (%)	145	109	36		

Male sex (%)	91 (62.3)	62 (56.9)	28 (77.8)	3.26 [1.21, 9.80]	0.025
qSOFA score ≥ 2 (%)	23 (16.1)	9 (8.5)	14 (38.9)	6.02 [2.09, 18.82]	0.001
Bilateral radiological infiltrate (%)	83 (56.8)	51 (46.8)	31 (86.1)	5.75 [1.91, 21.06]	0.004
C-reactive protein ≥ 40 mg/L (%)	86 (63.7)	53 (54.1)	32 (88.9)	4.73 [1.51, 18.58]	0.013

Discussion

Our study identified several risk factors for unfavourable disease progression leading to MV in patients admitted with COVID-19 in a Swiss university hospital.

A quarter of patients for which there were no limitation of care eventually required MV. MV occurred early during the course of hospitalization and the median duration of MV was shorter than previously reported [18]. This effect could result from selection bias of patients with no limitations of care and the limited duration of follow-up.

As infection with SARS-CoV-2 may cause an excessive host immune response, leading to ARDS and death [19]. We would expect biomarkers of inflammation to be associated with unfavourable outcomes. In this study, CRP >40 mg/L on admission was associated with higher odds of MV, suggesting that an unfavourable course is more frequent in patients with a severe inflammatory response related to the infection. Several studies have identified an increased risk of mortality in COVID-19 patients with elevated CRP [17,20]. Other biomarkers (for example, d-dimers) have also been identified as being associated with an increased risk of unfavourable outcome, but we did not identify this link in our study [6]. We believe that CRP is an ubiquitous biomarker whose result could potentially help clinicians assessing the

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

risk of MV in patients with COVID-19. Its use could be easily scaled up due to the availability of numerous point-of-care test. In our study, we noted an increase in the risk of mechanical ventilation for increasing score values for NEWS, CRB-65 and qSOFA. qSOFA has been proven a useful predictor of mortality among patients with suspected infection [13], mainly of bacterial aetiology [21], but also influenza [22,23]. We opted for including gSOFA in our final multivariate analysis, since it is widely used by clinicians in our institution, and is quick and easy to apply. A higher Sequential Organ Failure Assessment score (SOFA) has been previously linked to increased mortality due to COVID-19 [6]. Data for its calculation are not routinely collected for all patients outside the ICU, making it a less pragmatic tool to quickly evaluate the risk of MV in this patient population. We additionally identify male sex as a predictor of unfavourable outcome in patients with COVID-19, as previously described [24,25]. It is unclear why there is a sex unbalance in the risk for MV, which could originate in different host response to severe infection [26], notably SARS-CoV-2. Several factors such as obesity, pregnancy, healthcare worker status, nosocomial acquisition of SARS-CoV-2 infection, previous ACE inhibitors or ARB II treatment and immunosuppressive drugs before admission were not associated with severe disease in this study. Obesity has been described as a risk factor for ICU admission and mortality in patients with influenza [27,28], we found an association between obesity in COVID-19 patients with MV in the univariate, but not the multivariate analysis. Comorbidities generally associated with obesity may contribute in a higher degree to impaired outcomes explaining this finding. We did not identify any relationship between treatment with ECA inhibitors or ARB II and MV, although it has been suggested their use is associated to better outcomes in patients

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

admitted with SARS-CoV-2 [29]. Age was not risk factor for MV: numerous studies have linked age to mortality [2,6], but not to the need for MV. This could be due in part to the limitations of care agreed to in older patients. More than half of all admitted patients received a treatment with the intent of being specific for SARS-CoV-2, although no evidence for their efficacy exists [30]. A key unanswered question is whether these treatments have an impact on the clinical course of these patients. However, due to indication bias our study cannot answer this question, which should be addressed in prospective randomized clinical trials. Our study has several limitations to be acknowledged. First, due to its very nature the sample size is limited, which could lead to observation bias in the analyses, with some findings likely to evolve over time. The follow-up period was also limited and several patients were still hospitalised at the time of data analysis. Finally, due to the constantly evolving nature of the epidemic, the clinical care of patients likely evolved during their hospitalisation as changes were made to the recommendations for treatments administered at LUH. The single centre nature of the study limits the generalisability of the results. However, this study gives some valuable insights in the epidemiology and clinical course of patients admitted in our institution with SARS-CoV-2 infection. We found that male sex, bilateral SARS-CoV-2 pneumonia, elevated CRP and qSOFA equal or greater to two increased the risk of mechanical ventilation. The timely identification of these patients could help us target treatment and better manage the attribution of resources.

Notes Contributors JR wrote the protocol, participated in data acquisition and validation, performed the data analysis and drafted the manuscript. MP participated in data acquisition and validation, and in drafting the manuscript. RB participated in data acquisition and in drafting the manuscript. PF, JT, FD, BV, EK, LR, DH, MB, CF, KJ and AK participated in data acquisition. PAB, JLP and OM revised the protocol and the manuscript. LS revised the manuscript. LL took part in writing the protocol, in analysing the data, and in drafting the manuscript. All authors contributed to manuscript revision, read and approved the submitted version. References World Health Organization: Novel Coronavirus (2019-nCov) Situation Report-22. 1.

- 334 World Health Organization, 2020, February 11, 2020. Available:
- https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-
- 336 22-ncov.pdf?sfvrsn=fb6d49b1 2
- 337 2. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill
- 338 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
- observational study. Lancet Respir Med. 2020;0. doi:10.1016/S2213-2600(20)30079-5
- 340 3. World Health Organization: Novel Coronavirus (2019-nCov) Situation Report-22.
- 341 World Health Organization, 2020, March 11, 2020. Available:
- 342 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-
- 343 51-covid-19.pdf?sfvrsn=1ba62e57_10
- 344 4. https://www.bag.admin.ch/dam/bag/fr/dokumente/mt/k-und-i/aktuelle-
- 345 ausbrueche-pandemien/2019-nCoV/covid-19-lagebericht.pdf.download.pdf/COVID-
- 346 19 Situation epidemiologique en Suisse.pdf,accessed on the 1st April 2020. 2020.
- 347 5. Bai T, Tu S, Wei Y, Xiao L, Jin Y, Zhang L, et al. Clinical and Laboratory Factors
- 348 Predicting the Prognosis of Patients with COVID-19: An Analysis of 127 Patients in Wuhan,
- 349 China. Rochester, NY: Social Science Research Network; 2020 Feb. Report No.: ID 3546118.
- 350 Available: https://papers.ssrn.com/abstract=3546118
- 351 6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
- mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
- 353 The Lancet. 2020;0. doi:10.1016/S0140-6736(20)30566-3
- 354 7. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline
- 355 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs
- of the Lombardy Region, Italy. JAMA. 2020 [cited 9 Apr 2020]. doi:10.1001/jama.2020.5394
- 357 8. Wynants L, Calster BV, Bonten MMJ, Collins GS, Debray TPA, Vos MD, et al. Prediction

- 358 models for diagnosis and prognosis of covid-19 infection: systematic review and critical
- 359 appraisal. BMJ. 2020;369. doi:10.1136/bmj.m1328
- 360 9. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of
- 361 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25:
- 362 2000045. doi:10.2807/1560-7917.ES.2020.25.3.2000045
- 363 10. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
- 364 consortium: Building an international community of software platform partners. J Biomed
- 365 Inform. 2019;95: 103208. doi:10.1016/j.jbi.2019.103208
- 366 11. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA. 2012;307: 2526-
- 367 2533. doi:10.1001/jama.2012.5669
- 368 12. AKI Definition. Kidney Int Suppl. 2012;2: 19–36. doi:10.1038/kisup.2011.32
- 369 13. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.
- 370 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA.
- 371 2016;315: 801–810. doi:10.1001/jama.2016.0287
- 372 14. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ Study Group. CRB-65
- 373 predicts death from community-acquired pneumonia. J Intern Med. 2006;260: 93-101.
- 374 doi:10.1111/j.1365-2796.2006.01657.x
- 375 15. McGinley A, Pearse RM. A national early warning score for acutely ill patients. BMJ.
- 376 2012;345. doi:10.1136/bmj.e5310
- 377 16. Yan L, Zhang H-T, Goncalves J, Xiao Y, Wang M, Guo Y, et al. A machine learning-
- 378 based model for survival prediction in patients with severe COVID-19 infection. medRxiv.
- 379 2020; 2020.02.27.20028027. doi:10.1101/2020.02.27.20028027
- 380 17. Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, et al. A Tool to Early Predict Severe 2019-
- 381 Novel Coronavirus Pneumonia (COVID-19)2: A Multicenter Study using the Risk Nomogram

- 382 in Wuhan and Guangdong, China. medRxiv. 2020; 2020.03.17.20037515.
- 383 doi:10.1101/2020.03.17.20037515
- 384 18. Ling L, So C, Shum HP, Chan PKS, Lai CKC, Kandamby DH, et al. Critically ill patients
- 385 with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study. Crit
- 386 Care Resusc J Australas Acad Crit Care Med. 2020.
- 387 19. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-
- 388 19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8: 420-
- 389 422. doi:10.1016/S2213-2600(20)30076-X
- 390 20. Lu J, Hu S, Fan R, Liu Z, Yin X, Wang Q, et al. ACP Risk Grade: A Simple Mortality Index
- for Patients with Confirmed or Suspected Severe Acute Respiratory Syndrome Coronavirus 2
- 392 Disease (COVID-19) During the Early Stage of Outbreak in Wuhan, China. Rochester, NY:
- 393 Social Science Research Network; 2020 Feb. Report No.: ID 3543603. Available:
- 394 https://papers.ssrn.com/abstract=3543603
- 395 21. Maitra S, Som A, Bhattacharjee S. Accuracy of quick Sequential Organ Failure
- 396 Assessment (qSOFA) score and systemic inflammatory response syndrome (SIRS) criteria for
- 397 predicting mortality in hospitalized patients with suspected infection: a meta-analysis of
- 398 observational studies. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.
- 399 2018;24: 1123–1129. doi:10.1016/j.cmi.2018.03.032
- 400 22. Chang S-H, Yeh C-C, Chen Y-A, Hsu C-C, Chen J-H, Chen W-L, et al. Quick-SOFA score
- 401 to predict mortality among geriatric patients with influenza in the emergency department.
- 402 Medicine (Baltimore). 2019;98: e15966. doi:10.1097/MD.0000000000015966
- 403 23. Papadimitriou-Olivgeris M, Gkikopoulos N, Wüst M, Ballif A, Simonin V, Maulini M, et
- 404 al. Predictors of mortality of influenza virus infections in a Swiss Hospital during four
- 405 influenza seasons: Role of quick sequential organ failure assessment. Eur J Intern Med.

- 406 2020;74: 86–91. doi:10.1016/j.ejim.2019.12.022
- 407 24. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19
- 408 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care.
- 409 2020;24: 108. doi:10.1186/s13054-020-2833-7
- 410 25. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of
- 411 COVID-19 from Wuhan: A Retrospective Observational Study. Am J Respir Crit Care Med.
- 412 2020 [cited 9 Apr 2020]. doi:10.1164/rccm.202003-0543OC
- 413 26. Fish EN. The X-files in immunity: sex-based differences predispose immune
- 414 responses. Nat Rev Immunol. 2008;8: 737–744. doi:10.1038/nri2394
- 415 27. Fezeu L, Julia C, Henegar A, Bitu J, Hu FB, Grobbee DE, et al. Obesity is associated
- 416 with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a
- 417 systematic review and meta-analysis. Obes Rev Off J Int Assoc Study Obes. 2011;12: 653-
- 418 659. doi:10.1111/j.1467-789X.2011.00864.x
- 419 28. Sun Y, Wang Q, Yang G, Lin C, Zhang Y, Yang P. Weight and prognosis for influenza
- 420 A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: a systematic
- 421 review of observational studies with meta-analysis. Infect Dis Lond Engl. 2016;48: 813–822.
- 422 doi:10.1080/23744235.2016.1201721
- 423 29. Yang Guang, Tan Zihu, Zhou Ling, Yang Min, Peng Lang, Liu Jinjin, et al. Effects Of
- 424 ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19
- 425 Patients With Hypertension: A Single Center Retrospective Study. Hypertension. 0.
- 426 doi:10.1161/HYPERTENSIONAHA.120.15143

- 427 30. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in
- 428 Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020. doi:10.1056/NEJMoa2001282

- 430 Supporting information captions
- 431 S1 Table. Unadjusted risk factors associated with mechanical ventilation at 14 days

